Business
EUROBIO SCIENTIFIC: RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025
RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025 Revenue up 10% to €80.7 million Proprietary products account for 36% of revenue42% of revenue generated outside France 2025 results impacted by the transfer of EndoPredict®/Prolaris® production to FranceFree cash flow after investment of €4.4 millionNet debt of €-2.2 million including EB Development current account Paris, September 24, 2025 - 5:40 p.m. - Eurobio Scientific (FR0013240934, ALERS, eligible for PEA-PME), a leading French group in in
About this update from Eurobio-scientific Sa
[{"type":"image","alt":"Eurobio Scientific","displaySize":"","headline":null,"caption":"Eurobio Scientific","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/f9faa06825e5acb815281cbc2a20a33c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m45eRi4SxGSzLe.1oTz.Qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f9faa06825e5acb815281cbc2a20a33c","width":250,"height":71}},"lazy":false},{"type":"text","content":"RESULTS FOR THE FIRST SEMESTER OF FISCAL YEAR 2025","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue up 10% to €80.7 million","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Proprietary products account for 36% of revenue","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"42% of revenue generated outside France","length":39,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":86,"olType":false}]},{"val":[{"type":"text","content":"2025 results impacted by the transfer of EndoPredict®/Prolaris® production to France","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Free cash flow after investment of €4.4 million","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Net debt of €-2.2 million including EB Development current account","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":314,"olType":false},{"type":"text","content":"Paris, September 24, 2025 - 5:40 p.m. - Eurobio Scientific (FR0013240934, ALERS, eligible for PEA-PME), a leading French group in in vitro medical diagnostics and life sciences, today presents its consolidated results as of June 30, 2025, prepared in accordance with French standards and approved by the company's Board of Directors at its meeting on September 23, 2025.","length":374,"tagName":"p"},{"type":"text","content":"Eurobio Scientific's results as of June 30, 2025 show growth in activity, an improvement in gross margin linked to the increase in proprietary products, and a decline in EBITDA linked to pressure on distribution margins and transfer costs for EndoPredict®/Prolaris® production from Germany to France in the second quarter of 2025 (approximately €0.8 million). ","length":363,"tagName":"p"},{"type":"table","headerItems":[],"...